The most studied stimulatory checkpoint receptors and their ligands to date are mainly OX40, 4-1BB, and CD27, whose agonist in combination with PD-1/PD-L1 blockade are also being developed for the treatment of HNSCC (97, 98). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.